Dear reader of, please excuse the disruption. needs about $63500 in 2024. In 2023 we received donations of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 23,000 times a week, but only 75 people donate. If you find useful, please take a minute and support with your donation. Thank you!

Since 01.06.2021 is supported by the non-profit ADxS e.V..

$18094 of $63500 - as of 2024-04-30
Header Image
16. Sexual behavior with ADHD


16. Sexual behavior with ADHD

Women with ADHD have significantly1

  • Used to have their first sexual intercourse
  • Her first live birth earlier
  • Her menopause earlier

ADHD is associated with riskier sexual behavior.2
One study reported significantly reduced scores in adult women with ADHD in relation to3

  • Desire
  • Arousal
  • Orgasm
  • Satisfaction
  • Pain
  • Lubrication

In adult males with ADHD, the study reports significantly lower levels of

  • Orgasm
  • Erectile function
  • Sexual satisfaction
  • General satisfaction

Only desire was not affected in men.

Dopamine is associated with erectile function and male sexual behavior, and both too much and too little dopamine can be harmful.4 Dopamine appears to stimulate male sexual behavior and inhibit female sexual behavior.

Systemic administration of dopamine agonists by microinjection into the paraventricular nucleus of the hypothalamus (PVN) induces penile erection in male rats via dopamine D2 receptor activation. When microinjected into the medial preoptic area, they facilitate copulatory behavior. This is an activation of the inzertohypothalamic dopaminergic system, whose neurons originate in the catecholaminergic cell groups A13 and A14 of the hypothalamus.4 Unlike sildenafil, D2 agonists act directly in the CNS. The erectile response to D2 agonists is significantly reduced by the oxytocin antagonist d(CH2)5Tyr(Me)2-Orn8-vasotocin when it is administered intracerebroventricularly or into the VTA.
In the 1990s, a D4 agonist for the treatment of erectile dysfunction came onto the market. However, its success was limited, partly because orally active phosphodiesterase type V inhibitors were more effective and partly because the D4 agonist triggered vomiting.